Neuphoria urges stockholders to vote "FOR" both nominees on the WHITE proxy card.

Neuphoria Therapeutics is conducting a strategic alternatives review, which has garnered significant interest. The company urges shareholders to vote "FOR" both of its nominees on the WHITE proxy card. This comes after dissident stockholder Lynx1 Master Fund LP expressed interest in acquiring the company. Neuphoria's board is reviewing various options, including asset acquisitions, strategic pathways, and other alternatives to advance its neuropsychiatric disorder treatments.